News articles about Benitec Biopharma Limited (NASDAQ:BNTC) have trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Benitec Biopharma Limited earned a daily sentiment score of 0.25 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 44.4715559262377 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of Benitec Biopharma Limited (NASDAQ:BNTC) opened at 2.11 on Monday. The firm’s market cap is $21.64 million. The company has a 50-day moving average of $2.10 and a 200 day moving average of $2.43. Benitec Biopharma Limited has a one year low of $1.30 and a one year high of $5.48.
Several analysts recently weighed in on the stock. ValuEngine cut shares of Benitec Biopharma Limited from a “hold” rating to a “sell” rating in a report on Thursday. Maxim Group reaffirmed a “hold” rating on shares of Benitec Biopharma Limited in a report on Wednesday, May 31st.
ILLEGAL ACTIVITY NOTICE: “Benitec Biopharma Limited (BNTC) Earning Somewhat Positive Media Coverage, Report Shows” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/21/benitec-biopharma-limited-bntc-earning-somewhat-positive-media-coverage-report-shows.html.
Benitec Biopharma Limited Company Profile
Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic.
Receive News & Ratings for Benitec Biopharma Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma Limited and related companies with MarketBeat.com's FREE daily email newsletter.
